Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Pizotifen is a serotonin and tryptamine antagonist indicated for migraine prophylaxis. Pizotifen belongs to the class of antamines and is related to cyproheptadine.
- Mechanism
- Curator reviewed · 6 references
While the mechanism of action is not fully understood, it is proposed that pizotifen works by inhibiting the peripheral actions of serotonin and histamine in increasing the membrane permeability of cranial vessels and transudation of plasmakinin, while altering pain thresholds in migraines. By blocking 5-HT receptors, pizotifen attenuates the signalling of serotonin in causing cranial vasoconstriction, as well as serotonin-enhanced platelet function and aggregation. There is evidence that it also inhibits the peripheral actions of bradykinin. Pizotifen may inhibit serotonin reuptake by blood platelets, which affects the tonicity and decreases passive distension of extracranial arteries. The effects of pizotifen leading to appetite stimulation may be due to the drug acting at the metabolic level rather than a direct stimulation of the appetite centre.
- Primary indication
- Indicated for the prophylactic management of migraines.Curator reviewed · 1 structured indication
- Formula / weight
- C19H21NS · 295.44 g/mol (avg)
- First approval
- Canada, 2009
- Also known as
- Pizotyline
- Code names
- BC-105
- Brand names
- Sandomigran
Resolves to
FIADGNVRKBPQEU-UHFFFAOYSA-NSMILESCN1CCC(CC1)=C1C2=C(CCC3=CC=CC=C13)SC=C2What you can answer from here — as of September 23, 2026
Which drugs share a target with Pizotifen, and which of those have an active Phase 3 trial?